Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMink Therapeutics Inc

Mink Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.01 USD -0.28 ( 2.77%)
Last update at 2026-11-10T21:00:00Z
VOLUME
4288
Market Cap
58.23M

Momentum Score

…

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.00
Low
10.50
High
52 Week Price Range
8.48
Low
16.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mink Therapeutics Inc (NASDAQ: INKT) is a clinical-stage biopharmaceutical company that appears positioned to develop engineered innate immune cell therapies for oncology and immune-mediated diseases. Major long-term growth drivers may include progress in its clinical programs, validation of its platform in human studies, and partnerships or licensing that could support broader development and commercialization. Investors may find exposure to a platform-based cell therapy approach and potential clinical-readout milestones attractive for long-term upside.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.29
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.36
ROE
-1238.98%
Net Debt
-8.18M
ROCE
-1034.81%
Diluted EPS TTM
-2.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.49M -10.78M -22.46M -27.99M -30.21M
Net income -12.49M -10.78M -22.46M -24.78M -23.11M
Selling general administrative 6729.82M 4314.16M 7.43M 7.83M 4.64M
Selling and marketing expenses - 4310.07M 7423.88M - -
Gross profit -0.18M -0.22M -0.20M -28244.53M -28358.59M
Reconciled depreciation 0.18M 0.22M 0.19M 0.12M 0.08M
Ebit -12.49M -10.78M -22.46M -30.95M -28.36M
Ebitda -12.31M -10.57M -22.25M -30.83M -28.06M
Depreciation and amortization 0.18M 0.22M 0.20M 0.12M 0.30M
Non operating income net other - - - 2.70M -
Operating income -12.49M -10.65M -22.92M -30.95M -28.36M
Other operating expenses 12.49M 10.65M 22.92M 30.95M 18.61M
Interest expense - - - 0.25M 2.43M
Interest income 0.18M 0.17M 0.46M - -
Net interest income 0.18M 0.17M 0.56M 0.25M -2.43M
Income tax expense - -10774.02M 0.00M -3.21M -7.10M
Total revenue 0.00M 0.00M 0.00M 2704.74M 0.00M
Total operating expenses 12.31M 10.43M 22.72M 30.95M 18.61M
Cost of revenue 0.18M 0.22M 0.20M 30949.28M 28358.59M
Total other income expense net -0.01M -0.13M 0.46M 2.96M -1.85M
Net income from continuing ops -12.49M -10.78M -24.77M -27.99M -30.21M
Net income applicable to common shares - - - -27.99M -30.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.24M 5.72M 4.55M 21.47M 40.24M
Other current assets 0.49M 0.41M 0.23M 0.47M 0.72M
Total liab 28.47M 25.31M 22.61M 21.87M 16.47M
Total stockholder equity -14.23M -19.59M -18.06M -0.40M 23.78M
Other current liab 4.43M 4.23M 7.49M 6.86M 13.47M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -156.68M -144.18M -133.40M -110.94M -82.95M
Other assets - -732.20M 0.00M - -
Cash 13.36M 4.58M 3.37M 19.64M 38.89M
Total current liabilities 13.03M 6.96M 11.40M 12.68M 16.47M
Net debt -8.18M 0.35M -3.37M -19.64M -38.89M
Short term debt 5.18M - - - -
Short long term debt 5.18M - - - -
Short long term debt total 5.18M 4.92M - - -
Other stockholder equity 143.17M 125.23M 115.77M 110.83M 107.35M
Property plant equipment - - - 1.07M 0.61M
Total current assets 13.85M 4.99M 3.60M 20.40M 39.63M
Net tangible assets - - - -0.40M 23.78M
Short term investments - 4572.46M - - -
Net receivables - - - - 0.02M
Long term debt - 4.92M - - -
Inventory - - - - 0.00M
Accounts payable 3.43M 2.73M 3.91M 5.82M 3.00M
Accumulated other comprehensive income -0.72M -0.63M -0.43M -0.29M -0.63M
Common stock total equity - - - 0.00M -
Retained earnings total equity - - - -110.94M -
Non currrent assets other 390.48M 732.93M -0.00M 1.07M 0.00M
Non current assets total 0.39M 0.73M 0.95M 1.07M 0.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.20M -0.25M -0.25M
Change to liabilities - - - 6.09M -0.15M
Total cashflows from investing activities - - -0.07M -0.25M -0.25M
Net borrowings 0.00M 5.00M 0.00M - 9.46M
Total cash from financing activities 14.72M 10.82M -0.41M -0.16M 49.26M
Change to operating activities - - - - 3.89M
Net income -12.49M -10.78M -22.46M -27.99M -30.21M
Change in cash 8.78M 1.21M -16.27M -19.25M 36.20M
Begin period cash flow 4.58M 3.37M 19.64M 38.89M 2.69M
End period cash flow 13.36M 4.58M 3.37M 19.64M 38.89M
Total cash from operating activities -5.93M -9.56M -15.76M -18.87M -12.83M
Issuance of capital stock 14.45M 5.80M 0.00M 0.00M 39.80M
Depreciation 0.18M 0.22M 0.20M 0.12M 0.08M
Sale purchase of stock - 0.00M -0.48M -0.16M -
Other cashflows from financing activities -0.17M 0.02M 0.07M -293.52M 9.46M
Change to netincome - - - 3.03M 13.57M
Capital expenditures 0.00M 0.00M 0.07M 0.25M 0.25M
Cash flows other operating - - - -0.11M -
Cash and cash equivalents changes - - - -19.27M -
Change in working capital 3.29M 0.46M 2.90M 8.77M 3.74M
Stock based compensation 2.67M 1.81M 3.86M 3.03M 1.74M
Other non cash items 0.42M -1.26M -0.27M -2.79M 12.18M
Free cash flow -5.93M -9.56M -15.84M -19.12M -13.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
INKT
Mink Therapeutics Inc		 -0.28
2.77%		 10.01 - - - 11.33 -3.67
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Mink Therapeutics Inc

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

149 Fifth Avenue, New York, NY, United States, 10010

212 994 8250

https://minktherapeutics.com

15

Name Title Year Born
Dr. Garo H. Armen Ph.D. Exec. Chairman 1953
Dr. Jennifer S. Buell Ph.D. Pres, CEO & Director 1975
Dr. Marcus Antonius van Dijk Ph.D. Chief Scientific Officer 1962
Ms. Christine M. Klaskin Treasurer 1966
Mr. Patrick N. Jordan M.B.A. VP of Bus. Operations NA
Ms. Kimberly Ha Head of Investor Relations NA
Ms. Heather Boussios Gen. Counsel & Chief Compliance Officer NA
Joy Zhou Ph.D. VP & Head of CMC NA
Dr. Garo H. Armen Ph.D. Executive Chairman 1953
Dr. Jennifer S. Buell Ph.D. President, CEO & Director 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…